SCHEMBL3056644

SCHEMBL3056644

COC(=O)c1cscc1C(=O)Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.39
LMNA P02545 1/20 0.39
ALDH1A1 P00352 3/20 0.38
HSD17B10 Q99714 2/20 0.38
CFTR P13569 1/20 0.38
ABL1 P00519 1/20 0.38
MAPK8 P45983 1/20 0.38
MAPK9 P45984 1/20 0.38
MAPK10 P53779 1/20 0.38
KDM4E B2RXH2 5/20 0.37
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA7 P43166 2/20 0.37
CA9 Q16790 2/20 0.37
CA14 Q9ULX7 2/20 0.37
ATM Q13315 2/20 0.37
POLB P06746 1/20 0.37
PDK2 Q15119 1/20 0.37
PDK4 Q16654 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL68934 0.89 TSHR (0.46) TSHRLMNAALDH1A1HSD17B10CFTR
SCHEMBL13913259 0.81 PTPN1 (0.46) TSHRLMNAALDH1A1HSD17B10CFTR
SCHEMBL18047964 0.79 GSK3B (0.52) TSHRLMNAALDH1A1HSD17B10CFTR
SCHEMBL8197514 0.77 LMNA (0.50) TSHRLMNAALDH1A1HSD17B10CFTR
SCHEMBL2619615 0.77 CYP2A6 (0.45) TSHRLMNAALDH1A1HSD17B10CFTR
SCHEMBL28651663 0.76 TSHR (0.52) TSHRLMNAALDH1A1HSD17B10KDM4E
Cyclopropane SCHEMBL11664340 0.76 PTPN1 (0.42) TSHRLMNAALDH1A1HSD17B10CFTR
SCHEMBL14197656 0.76 MAPK8 (0.45) TSHRLMNAALDH1A1HSD17B10CFTR
SCHEMBL6056935 0.76 ABL1 (0.46) TSHRLMNAALDH1A1HSD17B10CFTR
SCHEMBL1527656 0.75 TSHR (0.39) TSHRLMNAALDH1A1HSD17B10CFTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541406-B2 Thiadiazole derivatives for the treatment of neurodegenerative diseases NV REMYND (BE) 2013-09-24 US disclosed
US-20100261707-A9 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2010-10-14 US disclosed
US-20090233911-A2 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-09-17 US disclosed
US-20090054410-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233911-A2 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 TSHR 3338/4885LMNA 1113/4885ALDH1A1 1930/4885
US-20100261707-A9 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 TSHR 3338/4885LMNA 1113/4885ALDH1A1 1930/4885
US-20090054410-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 TSHR 3338/4885LMNA 1113/4885ALDH1A1 1930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.